Commonwealth of Pennsylvania Public School Empls Retrmt SYS Purchases 180 Shares of Moderna, Inc. (NASDAQ:MRNA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 0.2% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 72,822 shares of the company’s stock after acquiring an additional 180 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Moderna were worth $7,760,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP lifted its stake in shares of Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares in the last quarter. TIAA Trust National Association lifted its position in Moderna by 2.3% during the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the period. Principle Wealth Partners LLC lifted its position in Moderna by 4.3% during the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC lifted its position in Moderna by 17.8% during the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Moderna by 32.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after purchasing an additional 116 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MRNA. Canaccord Genuity Group increased their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday, May 3rd. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. UBS Group increased their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Oppenheimer increased their price target on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $134.02.

Moderna Price Performance

Shares of NASDAQ MRNA traded up $3.66 during midday trading on Tuesday, reaching $125.14. The stock had a trading volume of 3,006,105 shares, compared to its average volume of 4,117,230. The stock has a 50-day moving average of $135.36 and a 200-day moving average of $114.41. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The company has a market capitalization of $47.96 billion, a price-to-earnings ratio of -7.99 and a beta of 1.67. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.19 earnings per share. As a group, research analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,296 shares of the firm’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $210,561.12. Following the completion of the transaction, the insider now directly owns 10,623 shares of the company’s stock, valued at $1,725,918.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Moderna news, CFO James M. Mock sold 648 shares of Moderna stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $105,280.56. Following the completion of the transaction, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at approximately $930,303.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Shannon Thyme Klinger sold 1,296 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $210,561.12. Following the completion of the sale, the insider now owns 10,623 shares of the company’s stock, valued at approximately $1,725,918.81. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 396,239 shares of company stock valued at $54,994,237. Corporate insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.